Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.
Frontiers in psychiatry January 1, 2023 Angela N Phan, Garth E Terry 6 citations
Cannabis use disorder affects about 2-5% of adults in the United States, and rates are expected to rise as cannabis restrictions loosen and THC content increases. No FDA-approved medications exist for this condition. Psychedelics have shown promise for other substance use disorders, and surveys suggest potential benefits for cannabis use disorder. A systematic review of the literature found only one study using the non-classical psychedelic ketamine for cannabis use disorder and three additional relevant articles. The review notes that psychedelics generally have a high therapeutic index with rare serious adverse effects, but risks such as psychosis and cardiovascular events should be considered in this population. More research is needed given rising incidence and interest in psychedelic treatments.